Work

Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.9063

Authors: Igor Puzanov, Mohammed M. Milhem, Robert Hans Ingemar Andtbacka, David R. Minor, Omid Hamid, Ai Li, Jeffrey Chou, Howard Kaufman

Institutions: Vanderbilt University Medical Center, University of Iowa Hospitals and Clinics, Huntsman Cancer Institute, Angeles Clinic and Research Institute, Amgen (United States), Rutgers Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2342031043

Cites:

Cited by: 43

Related to: 10